Differential prognostic significance of morphologic invasive markers in colorectal cancer: Tumor budding and cytoplasmic podia
Differential prognostic significance of morphologic invasive markers in colorectal cancer: Tumor budding and cytoplasmic podia
复制标题
DOI：
10.1007/s10350-006-0595-1
复制
发表时间：
2006-09-01
影响因子：
3.9
通讯作者：
Matsubara, Osamu
中科院分区：
文献类型：
--
作者：
Shinto, Eiji;Jass, Jeremy R.;Matsubara, Osamu
目的：在结直肠癌中，肿瘤出芽灶周围的细胞质足的存在可能是与细胞运动相关的激活出芽表型的形态学标志。在这项研究中，我们探讨了细胞质足的预后意义。方法：采用细胞角蛋白免疫染色法对136例pT3型结直肠癌进行分类，根据出芽程度和细胞质足部进行鉴定。然后评估出芽和细胞质足的预后意义。结果：高级别和低级别胞质足部组的总生存曲线不同（5年生存率分别为60.5%和83.8%,P = 0.0003）。肿瘤出芽的结果相似（59.8%和87.7%,P < 0.0001）。多因素分析显示，细胞质足部分级（危险比2.4,P = 0.012）和出芽（危险比2.3,P = 0.024）是独立的预后因素。此外，在高度出芽的结直肠癌中，胞质足的分级被选为独立的预后因素（危险比为2.4;P = 0.042）。结论：细胞质足和出芽是pT3型结直肠癌切除术患者相关但独立的病理预测指标。
PURPOSE: In colorectal cancer, the presence of cytoplasmic podia around tumor budding foci may be a morphologic marker for an activated budding phenotype that is associated with cell motility. In this study, we have investigated the prognostic significance of cytoplasmic podia. METHODS: A total of 136 pT3 colorectal cancers were classified according to extent of budding and cytoplasmic podia as identified by immunostaining for cytokeratin. The prognostic significance of budding and cytoplasmic podia was then assessed. RESULTS: The overall survival curves between the groups with high-grade and low-grade cytoplasmic podia were different (5-year survival rates were 60.5 and 83.8 percent respectively, P = 0.0003). Similar results were shown for tumor budding (59.8 and 87.7 percent, P < 0.0001). Multivariate analysis showed that the grades of cytoplasmic podia (hazards ratio, 2.4; P = 0.012) and budding (hazards ratio, 2.3; P = 0.024) were independent prognostic factors. Additionally, among colorectal cancers with high-grade budding, the grade of cytoplasmic podia was selected as an independent prognostic factor (hazards ratio, 2.4; P = 0.042). CONCLUSIONS: Cytoplasmic podia and budding are related but independent pathologic predictive markers in patients with resected pT3 colorectal cancer.